Contrast-Enhanced Mammography-Guided Breast Biopsy: Single-Center Experience

AJR Am J Roentgenol. 2023 Jun;220(6):826-827. doi: 10.2214/AJR.22.28780. Epub 2023 Feb 1.

Abstract

This prospective single-center study enrolled 50 women with 51 contrast-enhanced mammography (CEM)-enhancing lesions that lacked a sonographic or mammographic correlate. Trial participants underwent CEM-guided biopsy. Biopsy was technically successful for 46 lesions and was not performed for five nonvisualized lesions (all nonmass enhancement), yielding a cancellation rate of 9.8%. Mean biopsy time was 16.6 minutes. All biopsies revealed concordant pathology (25 benign, 10 high-risk, 11 malignant). No non-visualized or benign lesion yielded malignancy at follow-up.

Publication types

  • Clinical Trial

MeSH terms

  • Biopsy
  • Breast Neoplasms* / diagnostic imaging
  • Breast Neoplasms* / pathology
  • Breast* / pathology
  • Female
  • Humans
  • Image-Guided Biopsy
  • Mammography
  • Prospective Studies
  • Ultrasonography